Literature DB >> 15655521

2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice.

Atsufumi Kawabata1, Yuko Oono, Daiki Yonezawa, Kaori Hiramatsu, Naoki Inoi, Fumiko Sekiguchi, Masami Honjo, Michiko Hirofuchi, Toru Kanke, Hiroyuki Ishiwata.   

Abstract

1. Proteinase-activated receptor-2 (PAR(2)), expressed in capsaicin-sensitive sensory neurons, plays a protective role in gastric mucosa. The present study evaluated gastric mucosal cytoprotective effect of 2-furoyl-LIGRL-NH(2), a novel highly potent PAR(2) agonist, in ddY mice and in wild-type and PAR(2)-knockout mice of C57BL/6 background. 2. Gastric mucosal injury was created by oral administration of HCl/ethanol solution in the mice. The native PAR(2)-activating peptide SLIGRL-NH(2), administered intraperitoneally (i.p.) at 0.3-1 micromol kg(-1) in combination with amastatin, an aminopeptidase inhibitor, but not alone, revealed gastric mucosal protection in ddY mice, which was abolished by ablation of capsaicin-sensitive sensory neurons. 3. I.p. administration of 2-furoyl-LIGRL-NH(2) at 0.1 micromol kg(-1), without combined treatment with amastatin, exhibited gastric mucosal cytoprotective activity in ddY mice, the potency being much greater than SLIGRL-NH(2) in combination with amastatin. This effect was also inhibited by capsaicin pretreatment. 4. Oral administration of 2-furoyl-LIGRL-NH(2) at 0.003-0.03 micromol kg(-1) also protected against gastric mucosal lesion in a capsaicin-reversible manner in ddY mice. 5. I.p. 2-furoyl-LIGRL-NH(2) at 0.1-0.3 micromol kg(-1) caused prompt salivation in anesthetized mice, whereas its oral administration at 0.003-1 micromol kg(-1) was incapable of eliciting salivation. 6. In wild-type, but not PAR(2)-knockout, mice of C57BL/6 background, i.p. administration of 2-furoyl-LIGRL-NH(2) caused gastric mucosal protection. 7. Thus, 2-furoyl-LIGRL-NH(2) is considered a potent and orally available gastric mucosal protective agent. Our data also substantiate a role for PAR(2) in gastric mucosal protection and the selective nature of 2-furoyl-LIGRL-NH(2).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655521      PMCID: PMC1575994          DOI: 10.1038/sj.bjp.0706059

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2.

Authors:  Naoyuki Kawao; Hisao Ikeda; Tomoko Kitano; Ryotaro Kuroda; Fumiko Sekiguchi; Kazuo Kataoka; Yoshihisa Kamanaka; Atsufumi Kawabata
Journal:  J Pharmacol Sci       Date:  2004-03       Impact factor: 3.337

Review 2.  Protease-activated receptors: contribution to physiology and disease.

Authors:  Valeria S Ossovskaya; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

3.  Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice.

Authors:  M D Barrachina; V Martínez; L Wang; J Y Wei; Y Taché
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

4.  Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2.

Authors:  C U Corvera; O Déry; K McConalogue; S K Böhm; L M Khitin; G H Caughey; D G Payan; N W Bunnett
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

5.  Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue.

Authors:  M Saifeddine; B al-Ani; C H Cheng; L Wang; M D Hollenberg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

6.  Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo.

Authors:  Atsufumi Kawabata; Toru Kanke; Daiki Yonezawa; Tsuyoshi Ishiki; Masako Saka; Mototsugu Kabeya; Fumiko Sekiguchi; Satoko Kubo; Ryotaro Kuroda; Masahiro Iwaki; Kousaku Katsura; Robin Plevin
Journal:  J Pharmacol Exp Ther       Date:  2004-02-19       Impact factor: 4.030

7.  2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.

Authors:  John J McGuire; Mahmoud Saifeddine; Chris R Triggle; Kimberly Sun; Morley D Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2004-02-19       Impact factor: 4.030

Review 8.  Gastrointestinal functions of proteinase-activated receptors.

Authors:  Atsufumi Kawabata
Journal:  Life Sci       Date:  2003-12-05       Impact factor: 5.037

9.  The PAR-1-activating peptide facilitates pepsinogen secretion in rats.

Authors:  Naoyuki Kawao; Kaori Hiramatsu; Naoki Inoi; Ryotaro Kuroda; Hiroyuki Nishikawa; Fumiko Sekiguchi; Atsufumi Kawabata
Journal:  Peptides       Date:  2003-09       Impact factor: 3.750

Review 10.  PAR-2: structure, function and relevance to human diseases of the gastric mucosa.

Authors:  Atsufumi Kawabata
Journal:  Expert Rev Mol Med       Date:  2002-07-16       Impact factor: 5.600

View more
  9 in total

Review 1.  Gastrointestinal roles for proteinase-activated receptors in health and disease.

Authors:  A Kawabata; M Matsunami; F Sekiguchi
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

2.  Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells.

Authors:  Jacky Y Suen; Brooke Gardiner; Sean Grimmond; David P Fairlie
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

3.  Regulation of acid signaling in rat pulmonary sensory neurons by protease-activated receptor-2.

Authors:  Qihai Gu; Lu-Yuan Lee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-31       Impact factor: 5.464

4.  Suppression of pancreatitis-related allodynia/hyperalgesia by proteinase-activated receptor-2 in mice.

Authors:  Atsufumi Kawabata; Maho Matsunami; Masahiro Tsutsumi; Tsuyoshi Ishiki; Osamu Fukushima; Fumiko Sekiguchi; Naoyuki Kawao; Takeshi Minami; Toru Kanke; Naohiro Saito
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

5.  PAR4: a new role in the modulation of visceral nociception.

Authors:  S Bradesi
Journal:  Neurogastroenterol Motil       Date:  2009-11       Impact factor: 3.598

6.  Involvement of PAR2 in platelet-derived growth factor receptor-α-positive cell proliferation in the colon of diabetic mice.

Authors:  Yu-Jia Li; Jun-Ping Ao; Xu Huang; Hong-Li Lu; Han-Yue Fu; Ni-Na Song; Wen-Xie Xu; Jie Chen
Journal:  Physiol Rep       Date:  2021-11

7.  Investigating the role of MRGPRC11 and capsaicin-sensitive afferent nerves in the anti-influenza effects exerted by SLIGRL-amide in murine airways.

Authors:  Amy Y Chang; Tracy S Mann; Peter K McFawn; Liang Han; Xinzhong Dong; Peter J Henry
Journal:  Respir Res       Date:  2016-05-23

8.  The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects.

Authors:  Charlotte Avet; Claudio Sturino; Sébastien Grastilleur; Christian Le Gouill; Meriem Semache; Florence Gross; Louis Gendron; Youssef Bennani; Joseph A Mancini; Camil E Sayegh; Michel Bouvier
Journal:  Commun Biol       Date:  2020-11-27

9.  Protease-activated receptor 2 mediates human beta-defensin 2 and CC chemokine ligand 20 mRNA expression in response to proteases secreted by Porphyromonas gingivalis.

Authors:  Henrik Dommisch; Whasun O Chung; Maryam G Rohani; David Williams; Minnie Rangarajan; Mike A Curtis; Beverly A Dale
Journal:  Infect Immun       Date:  2007-06-25       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.